Christian Montanari1, Leslie K Kelley2, Tony M Kerr3, Maury Cole3, Nicholas W Gilpin2,4,5,6. 1. Department of Physiology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. cmont6@lsuhsc.edu. 2. Department of Physiology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. 3. La Jolla Alcohol Research Inc., La Jolla, CA, USA. 4. Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. 5. Alcohol & Drug Abuse Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. 6. Southeast Louisiana VA Healthcare System (SLVHCS), New Orleans, LA, 70119, USA.
Abstract
RATIONALE: Non-contingent chronic nicotine exposure procedures have evolved rapidly in recent years, culminating in electronic nicotine delivery systems (ENDS or e-cigarettes) to deliver vaporized drugs to rodents in standard housing chambers. OBJECTIVES: The aim of the current work was to use ENDS to test concentration-dependent effects of nicotine e-cigarette vapor inhalation on blood-nicotine concentrations, blood-cotinine concentrations, and somatic withdrawal signs over time in rats. METHODS: Male Wistar rats were exposed to vapor containing various concentrations of nicotine (20, 40, 80 mg/mL) for 11 days through ENDS, and blood concentrations of nicotine and cotinine, the major proximate metabolite of nicotine, as well as spontaneous and precipitated somatic withdrawal signs, were measured over time (across days of exposure and over hours after termination of vapor exposure). RESULTS: Exposing male Wistar rats to non-contingent nicotine vapor inhalation through ENDS produces somatic withdrawal symptoms and measurable blood-nicotine and blood-cotinine levels that change according to (1) concentration of nicotine in vape solution, (2) number of days of nicotine vapor exposure, (3) time since termination of nicotine vapor exposure, and (4) relative to the withdrawal signs, whether withdrawal was spontaneous or precipitated (by mecamylamine). CONCLUSIONS: The data presented here provide parameters that can be used as a reasonable starting point for future work that employs ENDS to deliver non-contingent nicotine vapor in rats, although many parameters can and should be altered to match the specific goals of future work.
RATIONALE: Non-contingent chronic nicotine exposure procedures have evolved rapidly in recent years, culminating in electronic nicotine delivery systems (ENDS or e-cigarettes) to deliver vaporized drugs to rodents in standard housing chambers. OBJECTIVES: The aim of the current work was to use ENDS to test concentration-dependent effects of nicotine e-cigarette vapor inhalation on blood-nicotine concentrations, blood-cotinine concentrations, and somatic withdrawal signs over time in rats. METHODS: Male Wistar rats were exposed to vapor containing various concentrations of nicotine (20, 40, 80 mg/mL) for 11 days through ENDS, and blood concentrations of nicotine and cotinine, the major proximate metabolite of nicotine, as well as spontaneous and precipitated somatic withdrawal signs, were measured over time (across days of exposure and over hours after termination of vapor exposure). RESULTS: Exposing male Wistar rats to non-contingent nicotine vapor inhalation through ENDS produces somatic withdrawal symptoms and measurable blood-nicotine and blood-cotinine levels that change according to (1) concentration of nicotine in vape solution, (2) number of days of nicotine vapor exposure, (3) time since termination of nicotine vapor exposure, and (4) relative to the withdrawal signs, whether withdrawal was spontaneous or precipitated (by mecamylamine). CONCLUSIONS: The data presented here provide parameters that can be used as a reasonable starting point for future work that employs ENDS to deliver non-contingent nicotine vapor in rats, although many parameters can and should be altered to match the specific goals of future work.
Authors: Catherine Ann Hess; Pablo Olmedo; Ana Navas-Acien; Walter Goessler; Joanna E Cohen; Ana Maria Rule Journal: Environ Res Date: 2016-10-28 Impact factor: 6.498
Authors: Janaina C M Vendruscolo; Brendan J Tunstall; Stephanie A Carmack; Brooke E Schmeichel; Emily G Lowery-Gionta; Maury Cole; Olivier George; Sophia A Vandewater; Michael A Taffe; George F Koob; Leandro F Vendruscolo Journal: Neuropsychopharmacology Date: 2017-08-16 Impact factor: 7.853
Authors: J D Nguyen; P T Bremer; C S Hwang; S A Vandewater; K C Collins; K M Creehan; K D Janda; M A Taffe Journal: Drug Alcohol Depend Date: 2017-04-14 Impact factor: 4.492
Authors: Mehrak Javadi-Paydar; Jacques D Nguyen; Tony M Kerr; Yanabel Grant; Sophia A Vandewater; Maury Cole; Michael A Taffe Journal: Psychopharmacology (Berl) Date: 2018-06-16 Impact factor: 4.530
Authors: Adam M Leventhal; David R Strong; Matthew G Kirkpatrick; Jennifer B Unger; Steve Sussman; Nathaniel R Riggs; Matthew D Stone; Rubin Khoddam; Jonathan M Samet; Janet Audrain-McGovern Journal: JAMA Date: 2015-08-18 Impact factor: 56.272
Authors: Briana Renda; Allyson K Andrade; Jude A Frie; Cassandra L Sgarbossa; Jennifer E Murray; Jibran Y Khokhar Journal: Drug Alcohol Depend Date: 2020-08-05 Impact factor: 4.492
Authors: Rodolfo J Flores; Fatima Z Alshbool; Priscilla Giner; Laura E O'Dell; Ian A Mendez Journal: Nicotine Tob Res Date: 2022-02-14 Impact factor: 5.825